BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20354751)

  • 1. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
    Chen Y; Ying M; Chen Y; Hu M; Lin Y; Chen D; Li X; Zhang M; Yun X; Zhou J; He E; Skog S
    Int J Clin Oncol; 2010 Aug; 15(4):359-68. PubMed ID: 20354751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
    Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
    Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay.
    Chen ZH; Huang SQ; Wang Y; Yang AZ; Wen J; Xu XH; Chen Y; Chen QB; Wang YH; He E; Zhou J; Skog S
    Sensors (Basel); 2011; 11(12):11064-80. PubMed ID: 22247653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
    Li HX; Lei DS; Wang XQ; Skog S; He Q
    Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression.
    Huang S; Lin J; Guo N; Zhang M; Yun X; Liu S; Zhou J; He E; Skog S
    Asian Pac J Cancer Prev; 2011; 12(2):497-505. PubMed ID: 21545220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.
    Li Z; Wang Y; He J; Ma J; Zhao L; Chen H; Li N; Zhou J; He E; Skog S
    Eur J Cancer Prev; 2010 Jul; 19(4):313-8. PubMed ID: 20479645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer.
    Zou L; Zhang PG; Zou S; Li Y; He Q
    Int J Biol Markers; 2002; 17(2):135-40. PubMed ID: 12113581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer.
    Larsson AM; Bendahl PO; Aaltonen K; Jansson S; Forsare C; Bergqvist M; Jørgensen CLT; Rydén L
    Sci Rep; 2020 Mar; 10(1):4484. PubMed ID: 32161278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours.
    Chen Z; Zhou H; Li S; He E; Hu J; Zhou J; Skog S
    Anticancer Res; 2008; 28(6B):3897-907. PubMed ID: 19192647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.
    Pan ZL; Ji XY; Shi YM; Zhou J; He E; Skog S
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1193-9. PubMed ID: 20140744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
    Jagarlamudi KK; Hansson LO; Eriksson S
    BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma.
    Li Z; Wang Y; Ma J; He J; Zhou J; He E; Skog S
    Anticancer Res; 2010 Apr; 30(4):1295-9. PubMed ID: 20530443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.
    Boyé P; Floch F; Serres F; Geeraert K; Clerson P; Siomboing X; Bergqvist M; Sack G; Tierny D
    J Vet Intern Med; 2019 Jul; 33(4):1728-1739. PubMed ID: 31129922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
    Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
    BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
    Tribukait B
    BMC Cancer; 2020 May; 20(1):440. PubMed ID: 32423477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of serum thymidine kinase 1 of 26 055 cases in health screening for early detection of premalignant/early malignant tumors].
    Cao X; Wang Y; Yang P; Zhou H; Liu C; Chen Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 39(10):1029-34. PubMed ID: 25355255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer.
    Liu Y; Ling Y; Qi Q; Tang Y; Xu J; Tong Z; Sheng G; Yang Q; Pan Y
    Exp Ther Med; 2011 Nov; 2(6):1177-1181. PubMed ID: 22977640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of correlation between serum thymidine kinase 1 and acute myeloid leukemia].
    Wang TJ; Sun AN; Wu DP; Li WY; Liang JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1095-8. PubMed ID: 24156413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people.
    Wang Y; Jiang X; Dong S; Shen J; Yu H; Zhou J; Li J; Ma H; He E; Skog S
    Cancer Biomark; 2016 Mar; 16(4):529-36. PubMed ID: 27002755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.